The endocannabinoid system and the treatment of obesity.
about
Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic miceRimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?ABC of obesity. Management: part II--drugs.Treatment options for obesity and potential therapies on the horizonDissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.Constitutive basal and stimulated human small bowel contractility is enhanced in obesity.Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.CB1 receptor antagonists: new discoveries leading to new perspectives.Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.Rimonabant: a novel approach for the treatment of obesity and cardiometabolic risk by blockade of the endocannabinoid system.Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes.Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations.Comparative genetics of the central nervous system in epigean and hypogean Astyanax mexicanus.The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure.Changes of Olfactory Performance during the Process of Aging - Psychophysical Testing and Its Relevance in the Fight against Malnutrition.Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women?Adiposopathy: why do adiposity and obesity cause metabolic disease?Dysregulation of cannabinoid CB1 receptor expression in subcutaneous adipocytes of obese individuals
P2860
Q27344569-5B80404B-8052-459A-BFBC-A3F670F65EAAQ34449870-A2C71983-8FE3-4861-9C58-D08864C06C7CQ34591803-F6006448-05D6-42DB-8114-D7A4029335E2Q35082872-03505398-A2C0-4B02-99CD-04E568BF2902Q35111291-ED58B938-A48F-41B0-A0BA-80D458056057Q37001332-AD6DF80D-16CF-47FC-9BE7-0BC596051BFAQ37169388-4633FBCF-6A24-4512-AFAE-74867150EF83Q37219313-E7E05D35-6F95-44F6-A304-CD3ECF984B95Q37359377-DA021C44-FF48-4B18-9813-F9450C33FE1AQ37998561-F2B39049-A1BF-4D7C-83EF-6405A1237976Q39959231-E2837237-1B11-462D-8F9F-0CE072CADEFFQ40179128-D1AEA996-29BB-43C6-9A90-CFE6A18E3A22Q42139803-82EB9BE1-FF11-4F56-BC03-A67FF9D288D9Q44854376-57D3FB3B-2CAE-4A5D-8D1B-FD83EC31F4EBQ44963212-6BF650B0-67B0-43D0-8FDB-66D7BF78B222Q46213429-E0F2F38B-BAAA-4F6C-863F-602B79914BF3Q50224101-DF150385-C811-41D2-BAAE-609FD549A2B3Q51391337-658C8C1F-BB92-4E20-AD1A-B79A5603E6D0Q56567724-7AE64665-E920-4390-B08A-85B6AAF74968Q58161351-91DD04F1-354F-4EEE-B529-A83C82E8C64F
P2860
The endocannabinoid system and the treatment of obesity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The endocannabinoid system and the treatment of obesity.
@ast
The endocannabinoid system and the treatment of obesity.
@en
type
label
The endocannabinoid system and the treatment of obesity.
@ast
The endocannabinoid system and the treatment of obesity.
@en
prefLabel
The endocannabinoid system and the treatment of obesity.
@ast
The endocannabinoid system and the treatment of obesity.
@en
P1433
P1476
The endocannabinoid system and the treatment of obesity.
@en
P2093
Renato Pasquali
Uberto Pagotto
P304
P356
10.1080/07853890510037419
P407
P577
2005-01-01T00:00:00Z